Bausch Health Companies (BHC) Non-Current Assets (2009 - 2026)
Bausch Health Companies (BHC) posted Non-Current Assets of $18.3 billion for Q2 2026, down 1.34% sequentially from $18.5 billion in Q1 2026, and down 11.95% YoY from $20.8 billion in Q2 2025.
Bausch Health Companies (BHC) Non-Current Assets (2009 - 2026) Analysis & Trends
Bausch Health Companies has reported Non-Current Assets for 18 years, with the latest figure at $18.3 billion in Q2 2026.
- Quarterly Non-Current Assets fell 11.95% year-over-year to $18.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $77.6 billion (down 6.96% YoY) and the FY2025 annual result came in at $20.2 billion, down 2.6% from the prior year.
- Non-Current Assets slipped to $18.3 billion in Q2 2026 per BHC's latest filing, from $18.5 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $23.3 billion in Q1 2022 and troughed at $18.3 billion in Q2 2026.
- A 5-year average of $21.1 billion and a median of $21.2 billion in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets increased 1.47% in 2023, then slipped 11.95% in 2026.
- Over 5 years, Non-Current Assets stood at $21.4 billion in 2022, then advanced by 1.47% to $21.8 billion in 2023, then retreated by 4.62% to $20.7 billion in 2024, then slipped by 2.6% to $20.2 billion in 2025, then fell by 9.58% to $18.3 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $18.3 billion, $18.5 billion, and $20.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Bausch Health Companies | 2.42 Bn | 586.38 Mn | 2.10 Bn | 18.27 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.27 Bn |
| Mar 31, 2026 | 18.52 Bn |
| Dec 31, 2025 | 20.21 Bn |
| Sep 30, 2025 | 20.58 Bn |
| Jun 30, 2025 | 20.75 Bn |
| Mar 31, 2025 | 20.69 Bn |
| Dec 31, 2024 | 20.75 Bn |
| Sep 30, 2024 | 21.19 Bn |
| Jun 30, 2024 | 21.28 Bn |
| Mar 31, 2024 | 21.52 Bn |
| Dec 31, 2023 | 21.75 Bn |
| Sep 30, 2023 | 22.02 Bn |
| Jun 30, 2023 | 21.04 Bn |
| Mar 31, 2023 | 21.21 Bn |
| Dec 31, 2022 | 21.44 Bn |
| Sep 30, 2022 | 22.29 Bn |
| Jun 30, 2022 | 22.75 Bn |
| Mar 31, 2022 | 23.25 Bn |
| Dec 31, 2021 | 23.60 Bn |
| Sep 30, 2021 | 23.93 Bn |